Results of the applicability of a population screening protocol for prostate cancer in Chapecó-SC
DOI:
https://doi.org/10.33448/rsd-v10i17.24465Keywords:
Prostate cancer; Screening programs; Prostate-Specific Antigen.Abstract
Campaigns that encourage screening for prostate cancer in Brazil are carried out annually and advocate the use of digital rectal examination associated with serum dosage of prostate-specific antigen. Objective: To evaluate the results and applicability of a prostate cancer screening protocol in Chapecó-SC. Methods: Clinical data from epidemiological profile questionnaires and PSA dosage tests of 249 men, over 45 years of age, residents of Chapecó-SC and affiliated to Unimed, were analyzed by consulting the Hospital's database and laboratory tests Unimed Chapecó. Results: The sample consisted of 249 men whose mean age was 51.2 years. The mean PSA value of the sample was 0.82 ng/dL and 3.2% of the patients had their result above 2.5 ng/dL. 14.05% have a history of a first-degree relative with prostate cancer. Discussion: Evidence suggests that screening for prostate cancer is not necessary. However, in the United States, the US Preventive Services Task Force recommended not performing screening and there was an increase in distant metastases of prostate cancer in individuals over 75 years of age. The most current recommendation indicates that it should be done individually in patients between 55 and 69 years old, for early-stage diagnosis and reduction of overdiagnosis and overtreatment. Conclusion: In view of the data presented, individualization in tracking is more important than indiscriminate population tracking.
References
Brasil. Resolução 466, de 12 de dezembro de 2012. Aprova diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Brasília: Conselho Nacional de Saúde, 2012
INCA. (2018). Câncer de próstata. INCA - Instituto Nacional de Câncer. https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata
Castro, H. A. S. D., Iared, W., Shigueoka, D. C., Mourão, J. E. & Ajzen, S. (2011). Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA entre 2, 6 e 10, 0 ng/ml. Radiologia Brasileira, 44, 205-9
Chou, R., Croswell, J. M., Dana, T., Bougatsos, C., Blazina, I., Fu, R., Gleitsmann, K., Koenig, H. C., Lam, C., Maltz, A., Rugge, J. B. & Lin, K. (2011). Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 155(11), 762. https://doi.org/10.7326/0003-4819-155-11-201112060-00375
De Souza Oliveira, E., da Paz Dias, M., Gomes Filho, E. R., Barbosa, N. B., & de Morais, A. C. L. N. (2020). Panorama clínico de pacientes submetidos à dosagem de antígeno prostático específico (PSA). Research, Society and Development, 9(9), e423997183-e423997183.
Demuner, B. B., & Carrijo-Carvalho, L. C. (2021). Avaliação de fatores de risco e antígeno prostático específico no rastreamento de câncer de próstata. Revista de Ciências Médicas e Biológicas, 20(2), 235-239.
Dos Santos Júnior, C. J., & Tôrres Oliveira, E. C. (2020). [ID 51955] Morbimortalidade por câncer de próstata em homens adultos em um estado do nordeste do brasil: caracterização epidemiológica e análise de tendência temporal. Revista Brasileira de Ciências Da Saúde, 24(4). https://doi.org/10.22478/ufpb.2317-6032.2020v24n4.51955
Faria, L., Pereira, P., Lustosa, A., Aragão, I., Aragão, F., & Cunha, M. (2020). Perfil epidemiológico do c ncer de próstata no brasil: retrato de uma década. Revista Uningá, 57(4), 76-84. Recuperado de http://revista.uninga.br/index.php/uninga/article/view/3336
Fontelles, M. J., Simões, M. G., Farias, S. H., & Fontelles, R. G. S. (2009). Metodologia da pesquisa científica: diretrizes para a elaboração de um protocolo de pesquisa. Revista paraense de medicina, 23(3), 1-8.
Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., & US Preventive Services Task Force. (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Jama, 319(18), 1901-1913.
Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L., Zappa, M., Nelen, V., & Auvinen, A. (2019). A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European urology, 76(1), 43-51.
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013). Screening for prostate cancer. The Cochrane Database of Systematic Reviews, 1, CD004720. https://doi.org/10.1002/14651858.CD004720.pub3
Jansen, R. J., Alexander, B. H., Anderson, K. E., & Church, T. R. (2013). Quantifying lead-time bias in risk factor studies of cancer through simulation. Annals of epidemiology, 23(11), 735-741.
Modesto, A. A. D. A., Lima, R. L. B. D., D’Angelis, A. C., & Augusto, D. K. (2017). Um novembro não tão azul: debatendo rastreamento de câncer de próstata e saúde do homem. Interface-Comunicação, Saúde, Educação.
Moyer, V. A. (2012). Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 157(2), 120. https://doi.org/10.7326/0003-4819-157-2-201207170-00459
Mulhem, E., Fulbright, N., & Duncan, N. (2015). Prostate Cancer Screening. American Family Physician, 92(8), 683–688. https://pubmed.ncbi.nlm.nih.gov/26554408/
Oncoguia, I. Fatores de Risco para Câncer de Próstata. Instituto Oncoguia. http://www.oncoguia.org.br/conteudo/fatores-de-risco-para-cancer-de-prostata/5850/1130/
Oncoguia, I. Sinais e Sintomas do Câncer de Próstata. Instituto Oncoguia. http://www.oncoguia.org.br/conteudo/sinais-e-sintomas-do-cancer-de-prostata/1188/289/
Patel, N. A., Sedrakyan, A., Bianco, F., Etzioni, R., Gorin, M. A., Hsu, W. C., & Hu, J. C. (2019, December). Definitive and sustained increase in
prostate cancer metastases in the United States. In Urologic Oncology: Seminars and Original Investigations. 37(12), 988-990. Elsevier.
Prostate Cancer: Early Detection Guideline - American Urological Association. Www.auanet.org. https://www.auanet.org/guidelines/guidelines/prostate-cancer-early-detection-guideline
Sarris, A. B., Candido, F. J. L. F., Pucci Filho, C. R., Staichak, R. L., Torrani, A. C. K., & Sobreiro, B. P. (2018). Câncer de próstata: uma breve revisão atualizada. Visão Acadêmica, 19(1).
Silva, F. A. da, Santos, F. C. B. dos, Sanches, M. H., Machado, R. L. D., & Furini, A. A. D. C. (2017). Serum level of prostate specific antigen in users of a clinical laboratory of Novo Horizonte, São Paulo. Revista Brasileira de Análises Clínicas, 49(1). https://doi.org/10.21877/2448-3877.201600526
Sociedade Brasileira de Urologia. Nota oficial 2017 - Rastreamento do Câncer de Próstata. Disponível em: https://sbu-sp.org.br/medicos/noticias/nota-oficial-2017-rastreamento-do-cancer-de-prostata/
Steffen, R. E., Trajman, A., Santos, M., & Caetano, R. (2018). Rastreamento populacional para o câncer de próstata: mais riscos que benefícios. Physis: Revista de Saúde Coletiva, 28, e280209.
Toebe, A. L., Figueró, N. A., Buhring, C. A. Z., & Mendes, G. A. (2020). Câncer de próstata: revisão da literatura acerca dos diversos aspectos da doença. Anais do Seminário Interinstitucional de Ensino, Pesquisa e Extensão.
Wroclawski, M. L. (2017). New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough. Einstein (São Paulo), 15(3), 7–10. https://doi.org/10.1590/s1679-45082017ed4151
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Gustavo Henrique Andrade; Luiza Pagnussatt; Thalis Matheus Fabiani ; Marcelo Zeni; Junir Antonio Lutinski
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
